Isabelle Whitehead, a student at Ripon Grammar School, has earned a place to study medicine, inspired by the care given to ...

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One ...

Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...

Isabelle Whitehead, a student at Ripon Grammar School, has earned a place to study medicine, inspired by the care given to her younger brother ...

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period - ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.5, a high estimate of $30.00, and a low estimate of $22.00. This upward trend is apparent, ...

HONG KONG SAR - Media OutReach Newswire - 8 August 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced its financial ...